{"entity":{"id":"nct07415863","kind":"trial","name":"Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SYS6043 in advanced solid tumours, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.","summary":"Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07415863 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 820 participants planned, started 2024-12-30 and due to reach its primary completion in 2027-12-30. Interventions recorded: SYS6043.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07415863","url":"https://clinicaltrials.gov/study/NCT07415863"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07415863","phase":"1/2","setting":"Phase I/II Dose-Escalation, PK Expansion and Cohort Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6043 in Patients With Advanced/Metastatic Solid Tumors","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","enrolled":820,"outcomes":[]},"route":"/trials/nct07415863/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}]}}